Affiliation:
1. 1Erasmus University Rotterdam;
2. 2Amsterdam UMC;
3. 3Cancer Center Amsterdam
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference8 articles.
1. Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma;Yamamoto;Blood.,2022
2. Modeling treatment sequences in pharmacoeconomic models;Zheng;PharmacoEconomics.,2017
3. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma;Attal;N Engl J Med.,2017
4. Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma;Patel;J Clin Oncol.,2021
5. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma;Dimopoulos;N Engl J Med.,2016
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献